Annual long term liabilities:
$4.46B+$777.80M(+21.11%)Summary
- As of today (May 24, 2025), REGN annual total long term liabilities is $4.46 billion, with the most recent change of +$777.80 million (+21.11%) on December 31, 2024.
- During the last 3 years, REGN annual long term liabilities has risen by +$1.73 billion (+63.22%).
- REGN annual long term liabilities is now at all-time high.
Performance
REGN Long term liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly long term liabilities:
$4.59B+$129.50M(+2.90%)Summary
- As of today (May 24, 2025), REGN quarterly total long term liabilities is $4.59 billion, with the most recent change of +$129.50 million (+2.90%) on March 31, 2025.
- Over the past year, REGN quarterly long term liabilities has increased by +$793.40 million (+20.89%).
- REGN quarterly long term liabilities is now at all-time high.
Performance
REGN quarterly long term liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Long term liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
REGN Long term liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +21.1% | +20.9% |
| 3 y3 years | +63.2% | +34.0% |
| 5 y5 years | +175.6% | +192.6% |
REGN Long term liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +63.2% | at high | +36.6% |
| 5 y | 5-year | at high | +175.6% | at high | +192.6% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
REGN Long term liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $4.59B(+2.9%) |
| Dec 2024 | $4.46B(+21.1%) | $4.46B(+0.1%) |
| Sep 2024 | - | $4.46B(+1.9%) |
| Jun 2024 | - | $4.37B(+15.1%) |
| Mar 2024 | - | $3.80B(+3.1%) |
| Dec 2023 | $3.68B(+8.1%) | $3.68B(+0.6%) |
| Sep 2023 | - | $3.66B(+3.5%) |
| Jun 2023 | - | $3.54B(+2.0%) |
| Mar 2023 | - | $3.46B(+1.6%) |
| Dec 2022 | $3.41B(+24.7%) | $3.41B(+1.5%) |
| Sep 2022 | - | $3.36B(-3.6%) |
| Jun 2022 | - | $3.48B(+1.7%) |
| Mar 2022 | - | $3.43B(+25.3%) |
| Dec 2021 | $2.73B(-20.6%) | $2.73B(+1.3%) |
| Sep 2021 | - | $2.70B(+2.8%) |
| Jun 2021 | - | $2.63B(+1.9%) |
| Mar 2021 | - | $2.58B(-25.1%) |
| Dec 2020 | $3.44B(+112.5%) | $3.44B(-5.0%) |
| Sep 2020 | - | $3.62B(+117.0%) |
| Jun 2020 | - | $1.67B(+6.3%) |
| Mar 2020 | - | $1.57B(-3.1%) |
| Dec 2019 | $1.62B(+5.5%) | $1.62B(-3.0%) |
| Sep 2019 | - | $1.67B(-2.1%) |
| Jun 2019 | - | $1.70B(-10.2%) |
| Mar 2019 | - | $1.90B(+23.7%) |
| Dec 2018 | $1.53B(+3.3%) | $1.53B(+0.9%) |
| Sep 2018 | - | $1.52B(+6.0%) |
| Jun 2018 | - | $1.43B(-6.8%) |
| Mar 2018 | - | $1.54B(+3.7%) |
| Dec 2017 | $1.48B(+15.7%) | $1.48B(-1.7%) |
| Sep 2017 | - | $1.51B(-2.9%) |
| Jun 2017 | - | $1.56B(-5.3%) |
| Mar 2017 | - | $1.64B(+28.1%) |
| Dec 2016 | $1.28B(+12.2%) | $1.28B(-6.8%) |
| Sep 2016 | - | $1.38B(+16.9%) |
| Jun 2016 | - | $1.18B(-3.5%) |
| Mar 2016 | - | $1.22B(+6.7%) |
| Dec 2015 | $1.14B(+80.7%) | $1.14B(-0.7%) |
| Sep 2015 | - | $1.15B(+96.1%) |
| Jun 2015 | - | $586.97M(-15.1%) |
| Mar 2015 | - | $691.01M(+9.2%) |
| Dec 2014 | $632.76M(-9.6%) | $632.76M(-18.6%) |
| Sep 2014 | - | $777.43M(+5.7%) |
| Jun 2014 | - | $735.66M(-1.1%) |
| Mar 2014 | - | $744.08M(+6.3%) |
| Dec 2013 | $700.10M(+4.3%) | $700.10M(+2.7%) |
| Sep 2013 | - | $681.52M(+0.1%) |
| Jun 2013 | - | $681.12M(+1.3%) |
| Mar 2013 | - | $672.41M(+0.1%) |
| Dec 2012 | $671.55M(-2.6%) | $671.55M(-0.7%) |
| Sep 2012 | - | $676.02M(-0.5%) |
| Jun 2012 | - | $679.62M(-0.9%) |
| Mar 2012 | - | $685.75M(-0.6%) |
| Dec 2011 | $689.58M(+52.4%) | $689.58M(+63.6%) |
| Sep 2011 | - | $421.54M(-2.6%) |
| Jun 2011 | - | $432.96M(-2.5%) |
| Mar 2011 | - | $443.95M(-1.9%) |
| Dec 2010 | $452.56M(+80.4%) | $452.56M(-1.7%) |
| Sep 2010 | - | $460.54M(+53.6%) |
| Jun 2010 | - | $299.85M(+1.0%) |
| Mar 2010 | - | $296.79M(+18.3%) |
| Dec 2009 | $250.87M(+14.5%) | $250.87M(+22.0%) |
| Sep 2009 | - | $205.58M(-2.8%) |
| Jun 2009 | - | $211.41M(+25.9%) |
| Mar 2009 | - | $167.99M(-23.3%) |
| Dec 2008 | $219.03M | $219.03M(+28.0%) |
| Sep 2008 | - | $171.19M(-2.9%) |
| Jun 2008 | - | $176.31M(-4.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2008 | - | $184.32M(-4.2%) |
| Dec 2007 | $192.33M(-40.5%) | $192.33M(-40.8%) |
| Sep 2007 | - | $325.01M(+3.6%) |
| Jun 2007 | - | $313.69M(-2.3%) |
| Mar 2007 | - | $321.14M(-0.7%) |
| Dec 2006 | $323.45M(+20.2%) | $323.45M(+24.4%) |
| Sep 2006 | - | $260.01M(-1.2%) |
| Jun 2006 | - | $263.06M(-1.1%) |
| Mar 2006 | - | $266.10M(-1.1%) |
| Dec 2005 | $269.14M(+5.0%) | $269.14M(+7.9%) |
| Sep 2005 | - | $249.37M(-1.0%) |
| Jun 2005 | - | $251.94M(-1.0%) |
| Mar 2005 | - | $254.58M(-0.7%) |
| Dec 2004 | $256.43M(-4.7%) | $256.43M(-0.6%) |
| Sep 2004 | - | $257.91M(-1.1%) |
| Jun 2004 | - | $260.67M(-1.9%) |
| Mar 2004 | - | $265.74M(-1.2%) |
| Dec 2003 | $268.99M(+30.9%) | $268.99M(-7.1%) |
| Sep 2003 | - | $289.56M(+38.8%) |
| Jun 2003 | - | $208.64M(+1.5%) |
| Mar 2003 | - | $205.46M(-0.0%) |
| Dec 2002 | $205.47M(-0.7%) | $205.47M(+0.2%) |
| Sep 2002 | - | $205.15M(-0.3%) |
| Jun 2002 | - | $205.81M(-0.3%) |
| Mar 2002 | - | $206.44M(-0.3%) |
| Dec 2001 | $207.02M(+1575.2%) | $207.02M(+2119.6%) |
| Sep 2001 | - | $9.33M(-7.4%) |
| Jun 2001 | - | $10.07M(-7.7%) |
| Mar 2001 | - | $10.92M(-11.6%) |
| Dec 2000 | $12.36M(-13.0%) | $12.36M(-2.0%) |
| Sep 2000 | - | $12.61M(-3.9%) |
| Jun 2000 | - | $13.12M(-6.2%) |
| Mar 2000 | - | $13.99M(-1.5%) |
| Dec 1999 | $14.20M(-12.9%) | $14.20M(-5.3%) |
| Sep 1999 | - | $15.00M(-4.5%) |
| Jun 1999 | - | $15.70M(-1.9%) |
| Mar 1999 | - | $16.00M(-1.8%) |
| Dec 1998 | $16.30M(-13.3%) | $16.30M(+2.5%) |
| Sep 1998 | - | $15.90M(-15.4%) |
| Jun 1998 | - | $18.80M(+1.6%) |
| Mar 1998 | - | $18.50M(-1.6%) |
| Dec 1997 | $18.80M(+0.5%) | $18.80M(+0.5%) |
| Sep 1997 | - | $18.70M(-3.1%) |
| Jun 1997 | - | $19.30M(+4.9%) |
| Mar 1997 | - | $18.40M(-1.6%) |
| Dec 1996 | $18.70M(+43.8%) | $18.70M(+6.9%) |
| Sep 1996 | - | $17.50M(+3.6%) |
| Jun 1996 | - | $16.90M(+24.3%) |
| Mar 1996 | - | $13.60M(+4.6%) |
| Dec 1995 | $13.00M(+41.3%) | $13.00M(+83.1%) |
| Sep 1995 | - | $7.10M(-9.0%) |
| Jun 1995 | - | $7.80M(-9.3%) |
| Mar 1995 | - | $8.60M(-6.5%) |
| Dec 1994 | $9.20M(+50.8%) | $9.20M(+13.6%) |
| Sep 1994 | - | $8.10M(+9.5%) |
| Jun 1994 | - | $7.40M(-10.8%) |
| Mar 1994 | - | $8.30M(+36.1%) |
| Dec 1993 | $6.10M(0.0%) | $6.10M(-4.7%) |
| Sep 1993 | - | $6.40M(-3.0%) |
| Jun 1993 | - | $6.60M(0.0%) |
| Mar 1993 | - | $6.60M(+8.2%) |
| Dec 1992 | $6.10M(+35.6%) | $6.10M(+8.9%) |
| Sep 1992 | - | $5.60M(+7.7%) |
| Jun 1992 | - | $5.20M(0.0%) |
| Mar 1992 | - | $5.20M(+15.6%) |
| Dec 1991 | $4.50M(-60.5%) | $4.50M(+28.6%) |
| Sep 1991 | - | $3.50M(-10.3%) |
| Jun 1991 | - | $3.90M(-65.8%) |
| Dec 1990 | $11.40M | $11.40M |
FAQ
- What is Regeneron Pharmaceuticals annual total long term liabilities?
- What is the all time high annual long term liabilities for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual long term liabilities year-on-year change?
- What is Regeneron Pharmaceuticals quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly long term liabilities year-on-year change?
What is Regeneron Pharmaceuticals annual total long term liabilities?
The current annual long term liabilities of REGN is $4.46B
What is the all time high annual long term liabilities for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual total long term liabilities is $4.46B
What is Regeneron Pharmaceuticals annual long term liabilities year-on-year change?
Over the past year, REGN annual total long term liabilities has changed by +$777.80M (+21.11%)
What is Regeneron Pharmaceuticals quarterly total long term liabilities?
The current quarterly long term liabilities of REGN is $4.59B
What is the all time high quarterly long term liabilities for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly total long term liabilities is $4.59B
What is Regeneron Pharmaceuticals quarterly long term liabilities year-on-year change?
Over the past year, REGN quarterly total long term liabilities has changed by +$793.40M (+20.89%)